Clinical TrialJul 9, 2026, 08:02 AM
IN8bio INB-200 Phase 1 GBM Data: mPFS 16.1 Months, >2x SOC
AI Summary
IN8bio announced the peer-reviewed publication of positive Phase 1 clinical data for its INB-200 (DeltEx DRI) therapy in newly diagnosed glioblastoma (GBM) patients in The Journal of Clinical Oncology. Repeat-dose patients achieved a median progression-free survival (mPFS) of 16.1 months, more than double the standard of care benchmark of approximately 6.9 months, with no dose-limiting toxicities. The therapy also showed a median overall survival of 19.5 months in repeat-dose patients, compared to 14.6 months for SOC.
Key Highlights
- INB-200 Phase 1 clinical data for glioblastoma published in The Journal of Clinical Oncology.
- Repeat-dose patients achieved a median progression-free survival (mPFS) of 16.1 months.
- This mPFS for repeat-dose patients was more than double the ~6.9-month standard of care benchmark.
- Median overall survival (mOS) in repeat-dose patients was 19.5 months, compared to ~14.6 months for SOC.
- The therapy demonstrated a well-tolerated safety profile with no DLTs, CRS, or ICANS observed.
- Across all 13 treated patients, mPFS was 9.9 months, a 43.5% improvement over SOC alone.
Price Impact
More from INAB